The Effect of Promiscuous Aggregation on in Vitro Drug Metabolism Assays.
Carvedilol
/ chemistry
Colloids
/ metabolism
Cytochrome P-450 Enzyme System
/ chemistry
Diclofenac
/ chemistry
Dihydropyridines
/ chemistry
Drug Interactions
High-Throughput Screening Assays
/ methods
Humans
Inhibitory Concentration 50
Kinetics
Metabolic Clearance Rate
/ drug effects
Microsomes, Liver
/ metabolism
Phenacetin
/ chemistry
Recombinant Proteins
/ chemistry
Solvents
/ chemistry
Tamoxifen
/ chemistry
Metabolism
non-specific inhibition
promiscuous aggregation
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
25 Oct 2019
25 Oct 2019
Historique:
received:
30
08
2019
accepted:
09
10
2019
entrez:
27
10
2019
pubmed:
28
10
2019
medline:
4
12
2019
Statut:
epublish
Résumé
Many bioactive molecules show a type of solution phase behavior, termed promiscuous aggregation, whereby at micromolar concentrations, colloidal drug-rich aggregates are formed in aqueous solution. These aggregates are known to be a major cause of false positives and false negatives in select enzymatic high-throughput screening assays. The goal of this study was to investigate the impact of drug-rich aggregates on in vitro drug screening metabolism assays. Cilnidipine was selected as an aggregate former and its impact on drug metabolism was evaluated against rCYP2D6, rCYP1A2, rCYP2C9 and human liver microsomes. The cilnidipine aggregates were shown to non-specifically inhibit multiple cytochrome P450 enzymes with an IC This newly demonstrated mode of "promiscuous inhibition" is of great importance as it can lead to false positives during drug metabolism evaluations and thus it needs to be considered in the future to better predict in vivo drug-drug interactions.
Identifiants
pubmed: 31654151
doi: 10.1007/s11095-019-2713-5
pii: 10.1007/s11095-019-2713-5
doi:
Substances chimiques
Colloids
0
Dihydropyridines
0
Recombinant Proteins
0
Solvents
0
Tamoxifen
094ZI81Y45
Carvedilol
0K47UL67F2
Diclofenac
144O8QL0L1
Cytochrome P-450 Enzyme System
9035-51-2
cilnidipine
97T5AZ1JIP
Phenacetin
ER0CTH01H9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Subventions
Organisme : Eli Lilly and Company
ID : N/A
Références
AAPS PharmSciTech. 2008;9(2):425-30
pubmed: 18431667
J Med Chem. 2003 Sep 25;46(20):4265-72
pubmed: 13678405
Langmuir. 2006 Jan 31;22(3):911-6
pubmed: 16430248
J Med Chem. 2003 Oct 9;46(21):4477-86
pubmed: 14521410
Drug Metab Dispos. 2003 Jul;31(7):815-32
pubmed: 12814957
J Pharm Sci. 2015 Aug;104(8):2583-93
pubmed: 26059413
Nat Rev Drug Discov. 2015 Jun;14(6):387-404
pubmed: 25907346
Pharm Res. 2015 Nov;32(11):3660-73
pubmed: 26123681
J Med Chem. 2002 Apr 11;45(8):1712-22
pubmed: 11931626
J Pharm Sci. 2010 Sep;99(9):3787-806
pubmed: 20623696
J Med Chem. 2010 May 27;53(10):4259-65
pubmed: 20426472
J Clin Pharmacol. 2003 May;43(5):443-69
pubmed: 12751267
Nat Protoc. 2006;1(2):550-3
pubmed: 17191086
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):909-22
pubmed: 18624679
Xenobiotica. 2007 Sep;37(9):986-99
pubmed: 17896325
J Pharm Sci. 2018 Jan;107(1):94-102
pubmed: 29031978
Nat Chem Biol. 2005 Aug;1(3):146-8
pubmed: 16408018
J Med Chem. 2009 Apr 9;52(7):2067-75
pubmed: 19281222
J Am Chem Soc. 2008 Jul 23;130(29):9606-12
pubmed: 18588298
Drug Metab Dispos. 2011 Apr;39(4):591-602
pubmed: 21212240
ACS Chem Biol. 2012 Aug 17;7(8):1429-35
pubmed: 22625864
J Control Release. 2016 May 10;229:172-182
pubmed: 27006280
Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65
pubmed: 18816299
Drug Metab Dispos. 2009 Dec;37(12):2330-9
pubmed: 19773538
J Med Chem. 2007 May 17;50(10):2385-90
pubmed: 17447748
J Med Chem. 2013 Mar 28;56(6):2406-14
pubmed: 23437772